Clinical Trials List
2021-09-30 - 2030-04-04
Phase III
Recruiting5
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Wen-Chien Chou Division of General Internal Medicine
- Chien-Chin Lin Division of General Internal Medicine
- MING YAO Division of General Internal Medicine
- Chieh-Lung Cheng Division of General Internal Medicine
- CHENG-HONG TSAI Division of General Internal Medicine
- - - Division of General Internal Medicine
- Huai-Hsuan Huang Division of General Internal Medicine
- - - Division of General Internal Medicine
- Tai-Chung Huang Division of General Internal Medicine
- 田豐銘 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王元欽 無
- HSUAN JEN SHIH 無
- 高小雯 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Tsung -Chih Chen Division of Hematology & Oncology
- ZHENG-WEI ZHOU 無
- PO-WEI LIAO 無
- 鄧齡喬 無
- CHENG-HSIEN LIN 無
- PO-HSIEN LI 無
- Chieh-Lin Teng Division of Hematology & Oncology
- HSIN-CHEN LIN 無
- 滕傑林 無
- YU-HSUAN SHIH 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ming-Yu Lien 無
- Chi-Ching Chen 無
- 王幸婷 無
- Ching-Chan Lin 無
- Ming-Hung Tsai Division of Hematology & Oncology
- 鄭富銘 無
- Che-Hung Lin 無
- 陳珈妤 無
- Tzu-Ting Chen 無
- 王秀慈 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
314 participants
